Apolipoprotein ε4 polymorphism does not modify the association between body mass index and high-density lipoprotein cholesterol: a cross-sectional cohort study

Lipids in Health and Disease

Luc Djoussé⁵  J Michael Gaziano⁵  R Curtis Ellison⁶  Steven C Hunt³  James S Pankow¹  Kari E North⁴  Donna K Arnett²  Catherine R Rahilly-Tierney⁵ 

[1] Division of Epidemiology & Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA;Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA;Cardiovascular Genetics Division, University of Utah, Salt Lake City, Utah, USA;Carolina Center for Genome Science, University of North Carolina Gillings School of Global Public Heatlh, Chapel Hill, North Carolina, USA;Harvard Medical School, Boston, Massachusetts, USA;Section of Preventive Medicine & Epidemiology, Boston University School of Medicine, Boston, Massachusetts, USA

关键词: adiposity;    lipid metabolism;    apolipoproteins;    genetic epidemiology;    body mass index;    HDL cholesterol;   

Others  :  1212504
DOI  :  10.1186/1476-511X-10-167

 received in 2011-08-02, accepted in 2011-09-23,  发布年份 2011

【 摘 要 】

Background

We sought to examine whether ε4 carrier status modifies the relation between body mass index (BMI) and HDL. The National Heart, Lung, and Blood Institute Family Heart Study included 657 families with high family risk scores for coronary heart disease and 588 randomly selected families of probands in the Framingham, Atherosclerosis Risk in Communities, and Utah Family Health Tree studies. We selected 1402 subjects who had ε4 carrier status available. We used generalized estimating equations to examine the interaction between BMI and ε4 allele carrier status on HDL after adjusting for age, gender, smoking, alcohol intake, mono- and poly-unsaturated fat intake, exercise, comorbidities, LDL, and family cluster.

Results

The mean (standard deviation) age of included subjects was 56.4(11.0) years and 47% were male. Adjusted means of HDL for normal, overweight, and obese BMI categories were 51.2(± 0.97), 45.0(± 0.75), and 41.6(± 0.93), respectively, among 397 ε4 carriers (p for trend < 0.0001) and 53.6(± 0.62), 51.3(± 0.49), and 45.0(± 0.62), respectively, among 1005 non-carriers of the ε4 allele (p-value for trend < 0.0001). There was no evidence for an interaction between BMI and ε4 status on HDL(p-value 0.39).

Conclusion

Our findings do not support an interaction between ε4 allele status and BMI on HDL.

【 授权许可】

   
2011 Rahilly-Tierney et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
• [2]Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bandiwala S, Tyroler HA: HDL cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
• [3]Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromsø heart-study: HDL and coronary heart-disease: a prospective case-control study. Lancet 1977, 1:965-968.
• [4]Perova NV, Organov RG, Williams DH, Irving SH, Abernathy JR, Deev AD, Shestov DB, Zhukovsky GS, Davis CE, Tyroler HA: Association of high-density-lipoprotein cholesterol with mortality and other risk factors for major chronic noncommunicable disease in samples of US and Russian men. Ann Epidemiol 1995, 5:179-185.
• [5]Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA: High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990, 131:32-47.
• [6]Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA: HDL cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986, 74:1217-1225.
• [7]Svensvold I, Urdal P, Thürmer H, Tverdal A, Lund-Larsen PG, Foss OP: HDL cholesterol and coronary, cardiovascular, and all cause mortality among middle-aged Norwegian men and women. Eur Heart J 1992, 13:1155-1163.
• [8]Enger SC, Hjermann I, Foss OP, Helgeland A, Holme I, Leren P, Norum KR: High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery 1979, 5:170-181.
• [9]Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:506-537.
• [10]Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994, 272:1666-1671.
• [11]Weisweiler P: Plasma lipoproteins and lipase and lecithin: cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab 1987, 65:969-973.
• [12]Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
• [13]Bowman TS, Kurth T, Sesso HD, Manson JE, Gaziano JM: Eight-year change in body mass index and subsequent risk of cardiovascular disease among healthy non-smoking men. Prev Med 2007, 45:436-441.
• [14]Lussier-Cacan S, Bolduc A, Xhignesse M, Niynsenga T, Connelly PW, Sing CF: Impact of age and body size on inter-individual variation in measures of lipid metabolism: influence of gender and apolipoprotein E genotype. Clin Genet 2000, 57:35-47.
• [15]Srinivasan SR, Ehnholm C, Elkasabany A, Berenson GS: Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: the Bogalusa Heart Study. Metabolism 2001, 50:696-702.
• [16]Kee F, Young IS, Poirier O, McMaster D, McCrum E, McGeough J, Patterson CC, Dallongeville J, Cambien F, Evans AE: Do polymorphisms of apoB, LPL or apoE affect the hypocholesterolemic response to weight loss? Atherosclerosis 2000, 153:119-128.
• [17]Higgins M, Province M, Heiss G, Eckfeldt J, Ellison RC, Folsom AR, Rao DC, Sprafka JM, Williams R: NHLBI Family Heart Study: objectives and design. Am J Epidemiol 1996, 143:1219-1228.
• [18]Corbo RM, Scacchi R: Apolipoproten E (APOE) allele distribution in the world. Is APOE*4 a "thrifty" allele? Ann Hum Genet 1999, 63:301-310.
• [19]Reymer PW, Groenemeyer BE, van de Burg R, Kastelein JJ: Apolipoprotein E genotyping on agarose gels. Clin Chem 1995, 41:1046-1047.
• [20]Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE: Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985, 122:51-65.
• [21]Criqui MH: Triglycerides and coronary heart disease revisited (again). Ann Intern Med 2007, 147:425-427.